Search results
Showing 271 to 285 of 456 results for chronic pain
Diroximel fumarate for treating relapsing–remitting multiple sclerosis (TA794)
Evidence-based recommendations on diroximel fumarate (Vumerity) for active relapsing–remitting multiple sclerosis in adults.
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)
Evidence-based recommendations on budesonide as an orodispersible tablet for inducing remission of eosinophilic oesophagitis in adults.
NICE has developed a medtech innovation briefing (MIB) on WoundExpress to manage lower leg wounds .
Autism spectrum disorder in adults: diagnosis and management (CG142)
This guideline covers diagnosing and managing suspected or confirmed autism spectrum disorder in people aged 18 and over. It aims to improve access and engagement with interventions and services, and the experience of care, for people with autism.
Tofacitinib for treating active ankylosing spondylitis (TA920)
Evidence-based recommendations on tofacitinib (Xeljanz) for treating active ankylosing spondylitis.
This guideline covers using psychosocial interventions to treat adults and young people over 16 who have a problem with or are dependent on opioids, stimulants or cannabis. It aims to reduce illicit drug use and improve people’s physical and mental health, relationships and employment.
Evidence-based recommendations on hand transplant surgery (allotransplantation). This involves transplanting a hand from a recently deceased donor onto the amputated stump.
View recommendations for HTG254Show all sections
Sections for HTG254
Evidence-based recommendations on lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema in adults. This involves diverting some of the lymphatic vessels around where lymph nodes have been removed to nearby veins.
View recommendations for HTG717Show all sections
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab (Simponi), tocilizumab (RoActemra) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried conventional DMARDs only but they have not worked.
Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)
Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in adults.
Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)
Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth failure in children.
Secukinumab for treating active non-radiographic axial spondyloarthritis (TA719)
Evidence-based recommendations on secukinumab (Cosentyx) for treating active non-radiographic axial spondyloarthritis in adults.
NICE has developed a medtech innovation briefing (MIB) on Peptest for diagnosing gastro-oesophageal reflux
Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making
Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for transfusion-dependent beta-thalassaemia in people 12 years and over.